PEY Invesco High Yield Equity Dividend Achievers ETF
- 20.660
- 0.0000.00%
Invesco High Yield Equity Dividend Achievers ETF To Go Ex-Dividend On May 20th, 2024 With 0.07567 USD Dividend Per Share
May 18th - $Invesco High Yield Equity Dividend Achievers ETF(PEY.US)$ is trading ex-dividend on May 20th, 2024. Shareholders of record on May 21st, 2024 will receive 0.07567 USD dividend per share
Moderna Vaccine Patent Upheld by European Patent Office: Report
'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The MRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, in a boon for the mRNA-vaccine maker in its ongoing legal fight to recoup pandem
Cracking The Code: Understanding Analyst Reviews For Verizon Communications
In the latest quarter, 7 analysts provided ratings for Verizon Communications (NYSE:VZ), showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below illu
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% of the issued share capital of Haleon.Following the settlem
Verizon Communications Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 28.71% Tigress Financial $50 → $52 Maintains Buy 04/23/2024 -0.99% Wells Fargo $44 → $40 Mainta
Altria Continues Gains for Eight Straight Sessions
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this
Vertical Research Upgrades 3M to Buy, Raises Price Target to $140
Vertical Research analyst Jeffrey Sprague upgrades 3M (NYSE:MMM) from Hold to Buy and raises the price target from $92 to $140.
3M Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 37.57% Vertical Research $92 → $140 Upgrades Hold → Buy 05/10/2024 13% HSBC $91.13 → $115 Upgra
GSK to Sell Entire Haleon Stake
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, j
Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million.What Happened: The settlement, disclosed in a Delaware
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Spotlight on Altria Group: Analyzing the Surge in Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Altria Group.Looking at options history for Altria Group (NYSE:MO) we detected 9 trades.If we consider the specifics of ea
Dividend Picks by SA Analysts: PFE, DVN, SBUX and LOW
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a gift.
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of ad
Walmart Remains Least Shorted S&P 500 Consumer Staple Stock in April
CNBC Halftime Report Final Trades: Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals, QUALCOMM
CNBC Halftime Report Final Trades: Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals, QUALCOMM